Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Compugen Ltd.NASDAQ: CGEN

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$7.66M, compared with -$7.15M a year earlier. Trailing-twelve-month income before tax was $34.88M.

Context

  • Income before tax amounted to 48.6% of revenue in FY2025, up 13.8 pp from a year earlier.
  • Income before tax increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$7.66M or moves back toward the trailing-twelve-month quarterly average of $8.72M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.66M-113.5% QoQ
Last fiscal yearDec 2025
$35.4M+464.6% YoY
LTMMar 2026
$34.88M+463.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.2%——
1 year+464.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
35.4M USD
Year-over-year change
+464.6%

Income Before Tax vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +463.6% is the highest of 9, against a peer median of -14.6%.
  • Income before tax amounts to 48.0% of revenue for CGEN, versus a peer median of 1764.5%.
CGEN Competitors
Income Before Tax for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026-$27.16M USD-34.7%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$36.23M USD+33.6%—1143.2%
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$147.39M USD-11.7%—839.5%
Peer median (excluding CGEN) —-14.6%—1764.5%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.